Human T-Lymphotropic virus type 1 and human immunodeficiency virus co-infection in rural Gabon. 2022

Augustin Mouinga-Ondémé, and Larson Boundenga, and Ingrid Précilya Koumba Koumba, and Antony Idam Mamimandjiami, and Abdoulaye Diané, and Jéordy Dimitri Engone-Ondo, and Delia Doreen Djuicy, and Jeanne Sica, and Landry Erik Mombo, and Antoine Gessain, and Avelin Aghokeng Fobang
Unité des Infections Rétrovirales et Pathologies Associées, Centre International de Recherches Médicales de Franceville (CIRMF), Franceville, Gabon.

Human T-cell lymphotrophic virus type-1 (HTLV-1) and human immunodeficiency virus (HIV-1) co-infection occur in many populations. People living with HIV-1 and infected with HTLV-1 seem more likely to progress rapidly towards AIDS. Both HTLV-1 and HIV-1 are endemic in Gabon (Central Africa). We investigated HTLV-1 and HIV-1 co-infection in the Haut-Ogooué province, and assessed factors that may favor the rapid evolution and progression to AIDS in co-infected patients. Plasma samples from HTLV-1 patients were tested using ELISA, and positive samples were then tested by western blot assay (WB). We used the polymerase chain reaction to detect HTLV-1 Tax/Rex genes using DNA extracted from the buffy coat of ELISA-positives samples. We recruited 299 individuals (mean age 46 years) including 90 (30%) men and 209 (70%) women, all of whom are under treatment at the Ambulatory Treatment Centre of the province. Of these, 45 were ELISA HTLV-1/2 seropositive. According to WB criteria, 21 of 45 were confirmed positive: 20 were HTLV-1 (44%), 1 was HTLV-1/2 (2%), 2 were indeterminate (4%) and 22 were seronegative (49%). PCR results showed that 23 individuals were positive for the Tax/Rex region. Considering both serological and molecular assays, the prevalence of HTLV-1 infection was estimated at 7.7%. Being a woman and increasing age were found to be independent risk factors for co-infection. Mean CD4+ cell counts were higher in HTLV-1/HIV-1 co-infected (578.1 (± 340.8) cells/mm3) than in HIV-1 mono-infected (481.0 (± 299.0) cells/mm3) Individuals. Similarly, the mean HIV-1 viral load was Log 3.0 (± 1.6) copies/ml in mono-infected and Log 2.3 (± 0.7) copies/ml in coinfected individuals. We described an overall high prevalence of HTLV-1/HIV-1 co-infection in Gabon. Our findings stress the need of strategies to prevent and manage these co-infections.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005681 Gabon A republic in west equatorial Africa, south of CAMEROON and west of the CONGO. Its capital is Libreville. Gabonese Republic
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D015153 Blotting, Western Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. Immunoblotting, Western,Western Blotting,Western Immunoblotting,Blot, Western,Immunoblot, Western,Western Blot,Western Immunoblot,Blots, Western,Blottings, Western,Immunoblots, Western,Immunoblottings, Western,Western Blots,Western Blottings,Western Immunoblots,Western Immunoblottings
D015367 Human T-lymphotropic virus 2 A strain of PRIMATE T-LYMPHOTROPIC VIRUS 2 that can transform normal T-lymphocytes and can replicate in both T- and B-cell lines. The virus is related to but distinct from HTLV-1. HTLV-2,HTLV-II,Human T-Cell Leukemia Virus II,Human T-Lymphotropic Virus II,Leukemia Virus II, Human T-Cell,T-Cell Leukemia Virus II, Human,Human T Cell Leukemia Virus II,Human T Lymphotropic Virus II,Leukemia Virus II, Human T Cell,T Cell Leukemia Virus II, Human,Human T lymphotropic virus 2
D015368 Human T-lymphotropic virus 1 A strain of PRIMATE T-LYMPHOTROPIC VIRUS 1 isolated from mature T4 cells in patients with T-lymphoproliferation malignancies. It causes adult T-cell leukemia (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), T-cell lymphoma (LYMPHOMA, T-CELL), and is involved in mycosis fungoides, SEZARY SYNDROME and tropical spastic paraparesis (PARAPARESIS, TROPICAL SPASTIC). ATLV,Adult T-Cell Leukemia-Lymphoma Virus I,HTLV-1,HTLV-I,Human T-Cell Leukemia Virus I,Leukemia Virus I, Human T-Cell,T-Cell Leukemia Virus I, Human,Adult T Cell Leukemia Lymphoma Virus I,Human T Cell Leukemia Virus I,Leukemia Lymphoma Virus I, Adult T Cell,Leukemia Virus I, Human T Cell,T Cell Leukemia Virus I, Human,Human T lymphotropic virus 1

Related Publications

Augustin Mouinga-Ondémé, and Larson Boundenga, and Ingrid Précilya Koumba Koumba, and Antony Idam Mamimandjiami, and Abdoulaye Diané, and Jéordy Dimitri Engone-Ondo, and Delia Doreen Djuicy, and Jeanne Sica, and Landry Erik Mombo, and Antoine Gessain, and Avelin Aghokeng Fobang
June 2000, Bailliere's best practice & research. Clinical haematology,
Augustin Mouinga-Ondémé, and Larson Boundenga, and Ingrid Précilya Koumba Koumba, and Antony Idam Mamimandjiami, and Abdoulaye Diané, and Jéordy Dimitri Engone-Ondo, and Delia Doreen Djuicy, and Jeanne Sica, and Landry Erik Mombo, and Antoine Gessain, and Avelin Aghokeng Fobang
January 2023, Revista do Instituto de Medicina Tropical de Sao Paulo,
Augustin Mouinga-Ondémé, and Larson Boundenga, and Ingrid Précilya Koumba Koumba, and Antony Idam Mamimandjiami, and Abdoulaye Diané, and Jéordy Dimitri Engone-Ondo, and Delia Doreen Djuicy, and Jeanne Sica, and Landry Erik Mombo, and Antoine Gessain, and Avelin Aghokeng Fobang
July 1997, The Journal of infectious diseases,
Augustin Mouinga-Ondémé, and Larson Boundenga, and Ingrid Précilya Koumba Koumba, and Antony Idam Mamimandjiami, and Abdoulaye Diané, and Jéordy Dimitri Engone-Ondo, and Delia Doreen Djuicy, and Jeanne Sica, and Landry Erik Mombo, and Antoine Gessain, and Avelin Aghokeng Fobang
April 2017, Human cell,
Augustin Mouinga-Ondémé, and Larson Boundenga, and Ingrid Précilya Koumba Koumba, and Antony Idam Mamimandjiami, and Abdoulaye Diané, and Jéordy Dimitri Engone-Ondo, and Delia Doreen Djuicy, and Jeanne Sica, and Landry Erik Mombo, and Antoine Gessain, and Avelin Aghokeng Fobang
May 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Augustin Mouinga-Ondémé, and Larson Boundenga, and Ingrid Précilya Koumba Koumba, and Antony Idam Mamimandjiami, and Abdoulaye Diané, and Jéordy Dimitri Engone-Ondo, and Delia Doreen Djuicy, and Jeanne Sica, and Landry Erik Mombo, and Antoine Gessain, and Avelin Aghokeng Fobang
May 1996, The Australasian journal of dermatology,
Augustin Mouinga-Ondémé, and Larson Boundenga, and Ingrid Précilya Koumba Koumba, and Antony Idam Mamimandjiami, and Abdoulaye Diané, and Jéordy Dimitri Engone-Ondo, and Delia Doreen Djuicy, and Jeanne Sica, and Landry Erik Mombo, and Antoine Gessain, and Avelin Aghokeng Fobang
August 1994, Journal of acquired immune deficiency syndromes,
Augustin Mouinga-Ondémé, and Larson Boundenga, and Ingrid Précilya Koumba Koumba, and Antony Idam Mamimandjiami, and Abdoulaye Diané, and Jéordy Dimitri Engone-Ondo, and Delia Doreen Djuicy, and Jeanne Sica, and Landry Erik Mombo, and Antoine Gessain, and Avelin Aghokeng Fobang
July 2017, AIDS (London, England),
Augustin Mouinga-Ondémé, and Larson Boundenga, and Ingrid Précilya Koumba Koumba, and Antony Idam Mamimandjiami, and Abdoulaye Diané, and Jéordy Dimitri Engone-Ondo, and Delia Doreen Djuicy, and Jeanne Sica, and Landry Erik Mombo, and Antoine Gessain, and Avelin Aghokeng Fobang
May 2012, Emerging infectious diseases,
Augustin Mouinga-Ondémé, and Larson Boundenga, and Ingrid Précilya Koumba Koumba, and Antony Idam Mamimandjiami, and Abdoulaye Diané, and Jéordy Dimitri Engone-Ondo, and Delia Doreen Djuicy, and Jeanne Sica, and Landry Erik Mombo, and Antoine Gessain, and Avelin Aghokeng Fobang
April 2009, Infectious disorders drug targets,
Copied contents to your clipboard!